ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing and gene insertion to develop new medicines. To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines. ReNAgade Therapeutics – RNA Without Limits
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $300M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.05.2023 | Series A | $300M | MPM Capita... |
Mentions in press and media 3
| Date | Title | Description |
| 24.05.2023 | ReNAgade Therapeutics Raises Over $300M in Series A Financing | ReNAgade Therapeutics, a Cambridge, MA-based biotechnology company developing RNA medicines, raised $300M in Series A funding. The round was led by MPM BioImpact and F2 Ventures. The company intends to use the funds to expand operations, an... |
| - | ReNAgade Therapeutics | “ReNAgade Therapeutics” |
| - | ReNAgade Therapeutics: This Company Recently Raised Over $300 Million To Develop RNA Medicines For Correcting Diseases | ReNAgade Therapeutics – a company unlocking the limitless potential for RNA medicines to correct disease – recently announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. The company has built a comprehensiv... |